Xiuwen Zhu

This inventor holds 22 USPTO granted patents and 20 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Arena Pharmaceuticals, Inc., Kumquat Biosciences Inc., The Burnham Institute. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiuwen Zhu. Retrieved from https://idiyas.com/inventor/xiuwen-zhu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 20)

% Patents Active = 95.5

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 15)

Average Co-Inventor Count = 7.3

ph-index = 6

Forward Citations = 116(Granted Patents)

Company Filing History:

18 out of 218

Arena Pharmaceuticals, Inc.

patents

3 out of 10

Kumquat Biosciences Inc.

patents

1 out of 94

The Burnham Institute

patents

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Cannabinoid Receptor Modulators

5-HT2C Receptor Agonists

S1P1 Receptor Agonists

Apoptosis Regulation

Autoimmune Disorders

Inflammatory Disorders

Tetrahydrocyclopenta Indoles

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365676 - Heterocyclic compounds and uses thereof (2025-07-22),

2. 12286427 - Heterocyclic compounds and uses thereof (2025-04-29),

3. 12209102 - Heterocyclic compounds and uses thereof (2025-01-28),

4. 12109219 - Cannabinoid receptor modulators (2024-10-08),

5. 11771695 - Cannabinoid receptor modulators (2023-10-03),

6. 11746091 - Cannabinoid receptor modulators (2023-09-05),

7. 11608339 - 5-HT2C receptor agonists and compositions and methods of use (2023-03-21),

8. 11214548 - Cannabinoid receptor modulators (2022-01-04),

9. 10836764 - 5-HT2C receptor agonists and compositions and methods of use (2020-11-17),

10. 10632134 - Cannabinoid receptor modulators (2020-04-28),

11. 10392390 - 5-HTreceptor agonists and compositions and methods of use (2019-08-27),

12. 9944606 - Cannabinoid receptor modulators (2018-04-17),

13. 9867822 - Cannabinoid receptor modulators (2018-01-16),

14. 9597340 - Cannabinoid receptor modulators (2017-03-21),

15. 9522133 - Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders (2016-12-20),

Title: A Spotlight on Innovator Xiuwen Zhu

Introduction

Xiuwen Zhu is an esteemed inventor located in San Diego, California, recognized for his significant contributions to the fields of pharmaceuticals and biotechnology. With an impressive portfolio of 20 patents, his work has paved the way for innovative therapeutic solutions.

Latest Patents

Among his latest patents, Xiuwen Zhu developed innovative heterocyclic compounds that provide methods for their use. These compounds and their pharmaceutically acceptable salts are particularly valuable for their utility as therapeutics, diagnostics, and research instruments. Notably, they have applications in reducing the signaling output of oncogenic proteins. Additionally, Zhu has focused on cannabinoid receptor modulators, providing methodologies for cancer treatment that involve compounds designed to modulate the activity of the cannabinoid CB receptor.

Career Highlights

Throughout his career, Xiuwen Zhu has made significant strides working with renowned organizations such as Arena Pharmaceuticals, Inc. and the Burnham Institute. His experience in these establishments enabled him to foster advancements in medicinal chemistry and drug development.

Collaborations

Xiuwen Zhu has had the pleasure of collaborating with notable colleagues, including Robert M. Jones and Sangdon Han. These partnerships have further enriched his innovative efforts and contributed to the success of various research projects in which he has participated.

Conclusion

In conclusion, Xiuwen Zhu stands out as a leading inventor in the biotechnology space. His cutting-edge patents and collaborations represent a commitment to improving healthcare outcomes. With ongoing contributions, he continues to influence the development of effective therapies in cancer treatment and beyond.

Profile summary based on public USPTO records.